Clinical trials: Blood Plasma Therapy
Osteoarthritis Knee, Corticosteroid
Intra-articular Platelet Rich Plasma vs Corticosteroid in Treatment of Knee Osteoarthritis Patients
Knee osteoarthritis is the most common type of osteoarthritis in the lower extremity and constitutes 23% of all arthritis cases, about 13% of females and 10% of males aged above 60 years have symptomatic knee OA.
- Conditions
- Osteoarthritis Knee, Corticosteroid, Platelet Rich Plasma
- Trial name
- NCT05742061
- Testing
- Corticosteroid, Platelet Rich Plasma
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Benha University
ExtraCorporeal Life Support (ECLS), Wound Infection
Investigating the Impact of Cold Atmospheric Plasma Treatment on Wound Healing at Cannulation Sites in Patients Following Extracorporeal Life Support
This study aims to evaluate a new wound treatment called cold atmospheric plasma (CAP) for patients receiving extracorporeal life support (ECLS).
- Conditions
- ExtraCorporeal Life Support (ECLS), Wound Infection, Surgical Site Infection, Delayed Wound Healing
- Trial name
- NCT07501897
- Testing
- Cold Atmospheric Plasma (CAP) Therapy, Standard wound care
- Where
- Taiwan
- Volunteers
- 65 people
- Sponsor
- National Taiwan University Hospital
Multiple Myeloma, Newly Diagnosed
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of autologous stem cell transplantation combined with BCMA CAR-T therapy followed by GPRC5D/CD3 bispecific antibody maintenance in…
- Trial name
- CAREMM-005 (NCT07106710)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, BCMA CAR-T, GPRC5D/CD3 BiTEs
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00743288
- Testing
- Melphalan, Panobinostat
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Oncotherapeutics
Type 2 Diabetes
Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
This study is designed to demonstrate the long-term safety of vildagliptin in patients with type 2 diabetes. This study will study vildagliptin as add-on therapy with metformin, thiazolidinedione, α-glucosidase inhibitor (α-GI)…
- Trial name
- NCT01159249
- Testing
- Vildagliptin
- Where
- 24 sites in Japan
- Volunteers
- 245 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye After LASIK-Laser in Situ Keratomileusis
Ocular Surface Syndrome Post-lasik, Outcomes of Treatment With Platelet Rich Plasma
To evaluate the efficacy of autologous platelet-rich plasma eye drops (E-PRP) for the treatment of chronic ocular surface syndrome (OSS) following laser in situ keratomileusis (LASIK).
- Trial name
- PRP-OSS (NCT03322917)
- Testing
- PRP autologous
- Volunteers
- 80 people
- Sponsor
- Vissum, Instituto Oftalmológico de Alicante
Multiple Myeloma
Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
This study will evaluate the efficacy and safety of LBH589B in adult patients with multiple myeloma who have received at least two prior therapies and are refractory to their last therapy.
- Trial name
- NCT00445068
- Testing
- LBH589
- Where
- 29 sites in United States, Germany
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B, Chronic
Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay
This non-interventional clinical study will be conducted to prospectively collect serial plasma samples from subjects with chronic HBV infection who are initiating antiviral therapy.
- Trial name
- HBVQuant (NCT02167113)
- Where
- 90 sites in United States, Australia and 8 more
- Volunteers
- 331 people
- Sponsor
- Hologic, Inc.
Multiple Myeloma, Minimal Residual Disease
A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment
The aim of this study was to observe the rate of MRD conversion and the impact on survival in newly diagnosed multiple myeloma (NDMM) patients with persistent MRD positivity after induction and consolidation therapy (autologous…
- Trial name
- MRD (NCT06109233)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- FengYan Jin
Corona Virus Infection
Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions
This study will provide access to investigational anti-SARS-CoV-2 human convalescent plasma for pediatric patients with underlying medical conditions (cardiovascular disease, lung disease, immunosuppression) who are either…
- Trial name
- NCT04462848
- Testing
- anti-SARS-CoV-2 human convalescent plasma
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
Plasma Cell Myeloma
Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
This study will test whether stopping maintenance therapy in people with multiple myeloma in MRD-negative remission has the same effect on disease control as continuing this therapy.
- Trial name
- NCT04221178
- Testing
- Cessation of continuous matinenace therapy
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma
Velcade (bortezomib), thalidomide and dexamethasone (VTD) has been demonstrated to be a highly effective combination in both patients with previously untreated and those with relapsed multiple myeloma.
- Trial name
- MUKsix (NCT02145715)
- Testing
- Velcade, Thalidomide, Dexamethasone
- Where
- 5 sites in United Kingdom
- Volunteers
- 54 people
- Sponsor
- Prof Jamie Cavenagh
Multiple Myeloma
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Patients with myeloma that has either not responded to previous treatment or has returned after previous treatment will be given a combination of the drugs bendamustine and bortezomib.
- Trial name
- NCT01315873
- Testing
- Bendamustine, Bortezomib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NYU Langone Health
Breast Cancer
Radiation Therapy in Treating Women With Invasive Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00301041
- Testing
- laboratory biomarker analysis, adjuvant therapy, radiation therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Shoulder Tendinopathy, Metabolic Alterations
Nutrition Impact on PRGF Treatment for Tendinopathy
Given the close correlation reported in the literature between onset and progression of tendon pathology in subjects affected by the alteration of metabolic disorders such as obesity, diabetes mellitus and lipidic metabolic…
- Trial name
- NUTRITENDON (NCT06536582)
- Testing
- Platelet rich growth factor injection (autologous product)
- Where
- Italy
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Bendamustine, Multiple Myeloma
Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma
Observe the best dose, efficacy and adverse reactions of BAd in the treatment of relapsed and refractory multiple myeloma.
- Trial name
- NCT05006469
- Testing
- Bendamustine
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Liao Aijun
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
RATIONALE: A personalized Internet-based program may help improve fatigue, depression, and quality of life in long-term survivors of stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00799461
- Testing
- internet-based intervention, questionnaire administration, psychosocial assessment and care
- Where
- United States
- Volunteers
- 1,337 people
- Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Multiple Myeloma and Plasma Cell Neoplasm
Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with dexamethasone may be an effective treatment for multiple myeloma.
- Trial name
- NCT00021359
- Testing
- dexamethasone, isotretinoin
- Where
- 18 sites in United States
- Volunteers
- 17 people
- Sponsor
- Fox Chase Cancer Center
Antibody-mediated Rejection, Autoimmune Reaction Mediated by Immune Complex
Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange
Therapeutic plasma exchange (TPE) is an established treatment modality for the acute removal of pathophysiological relevant mediators in various diseases.
- Trial name
- NCT02533596
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Hannover Medical School
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM)
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
- Trial name
- NCT04653246
- Testing
- Isatuximab, Lenalidomide, Bortezomib Injection
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jacob Laubach, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.